NXP900

Phase 1Small molecule

NNuvectis Pharma, Inc.

NXP900 is one of 45 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

EGFR Mutation Positive Non-Small Cell Lung CancerRecruiting

ALK PositiveRecruiting

Solid TumorPhase 1

Recruiting

EGFR Mutation Positive Non-Small Cell Lung CancerPhase 1

Recruiting

ALK PositivePhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 6

Navmi

SSummit Therapeutics

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

NXP900

NNuvectis Pharma, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

EGFR Mutation Positive Non-Small Cell Lung Cancer

NCT07315113

Q3 2027

Phase 1Recruiting

Solid Tumor

NCT05873686

Q1 2028

Phase 1Recruiting

ALK Positive

NCT07784959

Clinical

Trials by Indication[1]

ALK Positive1 trial

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

Recruiting·NNuvectis Pharma, Inc.·Phase 1·NCT07784959·54 enrolled

EGFR Mutation Positive Non-small Cell Lung Cancer1 trial

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

Recruiting·NNuvectis Pharma, Inc.·Phase 1·NCT07315113·18 enrolled

Solid Tumor1 trial

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Recruiting·NNuvectis Pharma, Inc.·Phase 1·NCT05873686·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NXP900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NXP900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NXP900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuvectis Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNuvectis Pharma, Inc.

NXP900

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Trials by Indication[1]

ALK Positive1 trial

EGFR Mutation Positive Non-small Cell Lung Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News